Lung Cancer: Types, Risk Factors, and Symptoms

Lung cancer is the leading cause of cancer-related death in the United States, accounting for more deaths annually than colorectal, breast, and prostate cancers combined, according to the National Cancer Institute (NCI). This page covers the major histological types of lung cancer, the established risk factors recognized by public health and regulatory bodies, and the clinical symptom patterns that prompt evaluation. Understanding these categories is foundational to grasping how diagnosis, staging, and treatment decisions are structured across oncology practice.

Definition and Scope

Lung cancer is defined by the uncontrolled proliferation of malignant cells originating in the lung tissue, most commonly in the bronchi, bronchioles, or alveoli. The National Cancer Institute classifies lung cancers into two primary histological groupings — non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) — based on cellular appearance under microscopy. This classification directly governs treatment pathway selection and is codified in staging frameworks published by the American Joint Committee on Cancer (AJCC).

Lung cancer's scope in the United States is substantial. The NCI estimated approximately 238,340 new cases of lung and bronchus cancer for 2023, making it the second most diagnosed cancer by incidence. The five-year relative survival rate for all stages combined is approximately 25 percent (NCI SEER Database), a figure that rises sharply when disease is detected at a localized stage.

The regulatory context for oncology, including coverage determinations for lung cancer screening under the Centers for Medicare & Medicaid Services (CMS), is shaped by these epidemiological realities. CMS covers annual low-dose computed tomography (LDCT) screening for adults aged 50 to 80 with a 20 pack-year smoking history under specific eligibility criteria (CMS Decision Memo CAG-00439N).

How It Works

Histological Classification

Non-Small Cell Lung Cancer (NSCLC) comprises roughly 80 to 85 percent of all lung cancer diagnoses (NCI). NSCLC is itself subdivided into three principal subtypes:

  1. Adenocarcinoma — The most common subtype in the United States, accounting for approximately 40 percent of lung cancers. It arises predominantly in peripheral lung tissue and is associated with both smoking and non-smoking patients. Adenocarcinoma frequently harbors targetable mutations such as EGFR, ALK, and ROS1 rearrangements.
  2. Squamous Cell Carcinoma (Epidermoid Carcinoma) — Accounts for approximately 25 to 30 percent of NSCLC cases. It typically originates in the central bronchi and is more strongly correlated with tobacco use than adenocarcinoma.
  3. Large Cell Carcinoma — A less differentiated subtype representing roughly 10 percent of NSCLC, diagnosed by exclusion when other histological patterns are absent.

Small Cell Lung Cancer (SCLC) represents approximately 13 to 15 percent of lung cancer cases (NCI). SCLC is characterized by rapid doubling time, early metastasis, and strong association with tobacco smoking. It is staged using a simplified two-stage system — limited stage and extensive stage — rather than the full TNM framework applied to NSCLC, reflecting its distinct biological behavior.

Molecular and Genomic Drivers

Molecular profiling and biomarker testing have become integral to NSCLC management. The National Comprehensive Cancer Network (NCCN) guidelines recommend biomarker testing for EGFR mutations, ALK rearrangements, ROS1 fusions, BRAF V600E mutations, MET exon 14 skipping, RET fusions, NTRK fusions, and PD-L1 expression levels in newly diagnosed advanced NSCLC. Each positive result can indicate eligibility for an FDA-approved targeted or immunotherapy agent.

Common Scenarios

Risk Factor Profiles

The Centers for Disease Control and Prevention (CDC) and the NCI identify the following established risk categories:

Symptom Presentation

Lung cancer symptoms vary by tumor location, size, and stage at detection. Central tumors involving the large bronchi tend to produce earlier, more pronounced symptoms; peripheral lesions may remain asymptomatic until advanced. Common symptom clusters include:

  1. Persistent cough — New or changed cough lasting more than 2 to 3 weeks, particularly with hemoptysis (blood in sputum).
  2. Dyspnea — Shortness of breath at rest or with minimal exertion.
  3. Chest pain — Dull, aching, or pleuritic pain that may worsen with deep breathing.
  4. Hoarseness — Resulting from recurrent laryngeal nerve involvement, more common in left-sided central tumors.
  5. Unexplained weight loss and fatigue — Systemic symptoms associated with advanced or metastatic disease. The relationship between these warning signs and cancer evaluation is examined further at unexplained weight loss and fatigue warning signs.
  6. Superior vena cava syndrome — Facial swelling, arm edema, and venous distension caused by tumor compression of the superior vena cava; more common with SCLC.
  7. Paraneoplastic syndromes — SCLC in particular can produce ectopic hormone secretion (e.g., ACTH, ADH) leading to metabolic and neurological presentations unrelated to direct tumor mass.

Symptoms that warrant formal cancer evaluation — including imaging and potential biopsy — are defined in clinical guidelines from the NCCN and the American College of Chest Physicians (ACCP).

Decision Boundaries

NSCLC vs. SCLC: Clinical Implications

The diagnostic boundary between NSCLC and SCLC is not merely taxonomic — it determines the entire treatment architecture. SCLC is almost never treated surgically due to its early systemic dissemination; first-line treatment consists of platinum-based chemotherapy with or without immunotherapy. NSCLC, by contrast, may be candidates for surgical resection, stereotactic body radiation therapy (SBRT), targeted therapy, immunotherapy, or combination regimens depending on stage, molecular profile, and performance status.

Screening-Eligible vs. Non-Eligible Populations

CMS screening criteria — age 50 to 80, 20 pack-year history, current smoker or quit within the past 15 years — define a specific population for annual LDCT. Patients outside these parameters are not covered under the CMS screening benefit, though clinical judgment may prompt evaluation through other diagnostic pathways such as those described in cancer screening guidelines.

Staging and Treatment Threshold

Cancer staging and grading using the AJCC TNM 8th edition system places NSCLC into stages I through IV. Stage I and II disease is typically addressed with curative-intent surgery or definitive radiation. Stage III disease, involving regional lymph node spread, is managed with concurrent chemoradiation and increasingly with consolidation immunotherapy (e.g., durvalumab following the PACIFIC trial). Stage IV disease is treated with systemic therapy selected based on biomarker status, with the FDA having approved more than 15 targeted agents for specific genomic alterations in NSCLC as of the NCI's treatment summary publications.

The decision to pursue clinical trials at any stage is governed by eligibility criteria tied to histology, prior treatment, and molecular profile — all of which loop back to the classification system described above.

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)